What's Happening?
The pharmaceutical industry is under increasing pressure to improve Environmental, Social, and Governance (ESG) performance across its supply chains. Driven by regulations such as CSRD and CSDDD, as well as rising expectations on human rights and decarbonisation,
pharma companies are navigating complex supply chains that contribute significantly to global GHG emissions. Experts from Nexio Projects highlight the need for pharma companies to focus on human rights, decarbonisation, and product carbon footprints to enhance sustainability. The industry faces challenges such as occupational health risks, modern slavery vulnerabilities, and high carbon emissions, necessitating strategic decarbonisation and robust human rights management.
Why It's Important?
Improving ESG performance is crucial for the pharmaceutical industry to maintain its reputation and meet regulatory requirements. As consumers increasingly demand ethically produced medicines, companies that fail to address human rights and environmental concerns risk losing market share. The focus on decarbonisation and human rights also presents opportunities for cost reductions and enhanced stakeholder trust. By prioritizing these areas, pharmaceutical companies can position themselves as leaders in sustainability, potentially gaining a competitive edge in the market.
What's Next?
Pharmaceutical companies are expected to implement comprehensive ESG strategies that integrate human rights and decarbonisation efforts. This may involve engaging suppliers, enhancing transparency, and adopting new technologies to reduce emissions. Companies will likely face increased scrutiny from regulators and consumers, prompting further investments in sustainability initiatives. The development of industry-specific standards and collaboration with stakeholders will be essential to drive meaningful progress and ensure compliance with evolving regulations.
